← Back
Data updated: Jun 28, 2026
HARM REDUCTION THERP
Pharma Pharmaceuticals
HARM REDUCTION THERP is a pharmaceutical company with 1 FDA-approved products.
2023
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
Upcoming FDA Decisions
Full Calendar → Aug 10, 2026 — Oveporexton (TAK-861)
30d Aug 19, 2026 — Garetosmab
Aug 23, 2026 — DTX401 (pariglasgene brecaparvovec)
HARM REDUCTION THERP's Key Drugs
HARM REDUCTION THERP's core commercial portfolio centers on RIVIVE — its most strategically important drugs approved in the last 15 years.
HARM REDUCTION THERP's Recent FDA Approvals
New NDA/BLA approvals for HARM REDUCTION THERP over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
HARM REDUCTION THERP's Therapeutic Areas
Disease areas where HARM REDUCTION THERP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HARM REDUCTION THERP Pipeline Snapshot
Active clinical trials for HARM REDUCTION THERP across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RIVIVE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-07-28
- Latest
- 2023-07-28
- Applications
- 1